Business Context and Reporting Period
This Form 8-K Current Report was filed by MediciNova, Inc. (Nasdaq: MNOV) on May 17, 2021. The report addresses a corporate governance event under Item 8.01 (Other Events).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The material change reported is the appointment of David H. Crean, Ph.D., as Chief Business Officer. Dr. Crean brings extensive experience in the biopharmaceutical industry, including roles as President and CEO of Coast BioVentures LLC and Managing Partner at Cardiff Advisory LLC. He previously served as Managing Director for Objective Capital Partners, LLC.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on future performance, or discussion of risks and contingencies. The document serves solely to disclose the executive appointment.
Key Facts for Investor Verification
- David H. Crean, Ph.D., has been appointed Chief Business Officer.
- Dr. Crean holds an MBA from Pepperdine University and a Ph.D. in Biophysics from the State University of New York at Buffalo.
- He currently serves as Board Chairman for Histogen, Inc. (Nasdaq: HSTO).
- He holds FINRA Series 79 and Series 63 licenses.
- The appointment was announced on May 17, 2021, and the report was signed by President and CEO Yuichi Iwaki, M.D., Ph.D., on May 18, 2021.